Who is sponsoring NCT04359238?

NCT04359238 is sponsored by University Hospital Heidelberg.

What drugs are being tested in NCT04359238?

Interventions in NCT04359238: Individualized excercise.

What condition does NCT04359238 study?

NCT04359238 studies Cardiomyopathy, Dilated, Heart Failure.

Is NCT04359238 still recruiting?

NCT04359238 is currently completed. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT04359238: ACTIVE-DCM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

activeDCM - Interventional Clinical Trial of Individualized Activity and Exercise Programs to Improve Outcome in Dilated Cardiomyopathy Guided by Longitudinal Biosensing With Apple Watch

Completed NA Last updated 24 March 2026

What this trial tests

NA trial testing Individualized excercise in Cardiomyopathy, Dilated in 300 participants. Completed in 4 July 2025.

Timeline

1 June 2020

Primary endpoint
1 April 2024

4 July 2025

Quick facts

Lead sponsor	University Hospital Heidelberg
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	1 June 2020
Primary completion	1 April 2024
Estimated completion	4 July 2025
Sites	1 location across Germany

Drugs / interventions tested

Individualized excercise

Conditions studied

Cardiomyopathy, Dilated — all drugs for Cardiomyopathy, Dilated →
Heart Failure — all drugs for Heart Failure →

Sponsor

University Hospital Heidelberg

Who can join

Adults 18 to 65, any sex, with Cardiomyopathy, Dilated or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The influence of an individualized sports program on dilated cardiomyopathy patients will be investigated in a randomized, prospective intervention study. 300 patients with dilated cardiomyopathy are included and examined over a period of 13 months. All participants will receive an Apple Watch, which serves for monitoring of activity and symptoms.The primary endpoint of the study is the change in maximum oxygen intake. In addition, the changes in well-being, objective parameters of cardiac function and the subject's compliance to his excercise program are of interest as secondary endpoints and for further exploratory research. In addition, the safety of a personalized sports program is evaluated. Molecules circulating in the blood (including proteins, RNA) are beeing measured at the beginning and in the course of the training program in order to be able to derive a connection between the training and the changed cardiovascular function. A gene analysis will be carried out, which serves to identify the genetic requirements of protective excercise.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Artificial intelligence to improve cardiovascular population health.
Meder B, Asselbergs FW, Ashley E. · · 2025 · cited 10× · PMID 40106837 · DOI 10.1093/eurheartj/ehaf125
A Remote Patient Monitoring System With Feedback Mechanisms Using a Smartwatch: Concept, Implementation, and Evaluation Based on the activeDCM Randomized Controlled Trial.
Wettstein R, Sedaghat-Hamedani F, Heinze O, Amr A, et al · · 2024 · cited 6× · PMID 39365164 · DOI 10.2196/58441
Personalized care in dilated cardiomyopathy: Rationale and study design of the activeDCM trial.
Sedaghat-Hamedani F, Amr A, Betz T, Kayvanpour E, et al · · 2024 · cited 4× · PMID 39010317 · DOI 10.1002/ehf2.14970

Verify or expand the search:

Other recruiting trials for Cardiomyopathy, Dilated

Currently open trials in the same condition.

NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
NCT06091475 — Therapy to Maintain Remission in Dilated Cardiomyopathy · NA · recruiting
NCT05981092 — A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) · active not recruiting
NCT05321875 — Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial) · Phase 3 · recruiting
NCT07527715 — Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy · recruiting

Other University Hospital Heidelberg trials

Trials by the same sponsor.

NCT07388147 — Exercise Therapy for Multiple Myeloma Patients · NA · not yet recruiting
NCT07348874 — Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany · not yet recruiting
NCT07181928 — Is Mentalization-based Therapy More Effective Than Treatment-as-usual for Adolescents With Dissocial Disorders? · NA · not yet recruiting
NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04359238 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Heidelberg
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04359238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing